Loading clinical trials...
Loading clinical trials...
Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER)
Conditions
Interventions
Trastuzumab (neoadjuvant)
Pertuzumab (neoadjuvant)
+1 more
Locations
1
Spain
Institut Català d'Oncologia l'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Start Date
March 22, 2021
Primary Completion Date
June 1, 2024
Completion Date
December 1, 2024
Last Updated
September 29, 2023
NCT04550494
NCT05372640
NCT07169851
NCT00026884
NCT05245812
NCT07159659
Lead Sponsor
Institut Català d'Oncologia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions